CD19 and acute lymphoblastic leukemia: Blinatumomab, a BiTE targeting CD19 and CD3, was approved by the Food and Drug Administration (FDA) in 2014 for relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) [7].